Andrew D. Zelenetz

Andrew D. Zelenetz, MD, PhD is Attending Physician on the Lymphoma Service and Medical Director of Quality Informatics at Memorial Sloan Kettering Cancer Center, and Professor of Medicine at Weill Cornell Medical College. He is one of the most influential figures in the design and dissemination of DLBCL treatment standards globally. Dr. Zelenetz is recognized for his foundational leadership of the NCCN B-Cell Lymphomas clinical practice guidelines panel, which he has chaired for more than two decades, developing the framework that guides front-line and salvage therapy decisions for DLBCL and follicular lymphoma in the United States and internationally. He was a principal investigator in the POLARIX trial (NEJM 2022), a phase III study demonstrating that polatuzumab vedotin plus R-CHP (pola-R-CHP) significantly improved progression-free survival compared with standard R-CHOP in previously untreated DLBCL, representing the first positive phase III trial to improve upon R-CHOP in over two decades and leading to FDA approval of pola-R-CHP. Dr. Zelenetz's research spans clonal B-cell biology, circulating tumor DNA (ctDNA) applications in lymphoma management, CAR-T cell therapy access and outcomes, and biosimilar rituximab implementation. He has authored more than 300 peer-reviewed publications and is a founding contributor to MSK's integrated genomic lymphoma profiling programs.